OncoMethylome Sciences Changes its Name to MDxHealth
OncoMethylome Sciences SA announced that its Extraordinary General Shareholders' Meeting passed the resolution on the proposed name change of the company to MDxHealth SA. The name change was unanimously supported by the shareholders present or represented at the meeting.
As announced in the 2010 half-year results, MDxHealth is finalizing a new strategy that focuses on high-value oncology based molecular diagnostic testing for personalized medicine. The aim of this new strategy is to reap the full benefits of the company's world-leading methylation platform by developing DNA-biomarkers as stand-alone cancer diagnostics. The company has moved away from its original model as a pure discovery company which out-licensed biomarkers to third party developers and distributors. In the new strategy, the company will end-develop products itself and sell them directly to treating physicians and to pharmaceutical companies. This new strategy will enable the company to control product development and sales rather than being entirely dependent on partners.
To fully reflect the change in strategy and better position the company towards patients, physicians and new pharmaceutical partners, management and the Board of Directors proposed MDxHealth as the new name of the company. The name change is particularly important for the company's direct sales to treating physicians who want healthcare solutions. The company believes that "MDxHealth" captures its new aspirations. "MDx", short for molecular diagnostics, has rapidly become one of the key areas of healthcare innovation and progress; an area where diagnostics and therapeutics converge. While "Health" is really what the company's work is all about: assisting physicians to improve the life and health of cancer patients. "MDxHealth" conveys the company's renewed mission: to develop and commercialize advanced molecular diagnostic tests for personalized cancer treatment.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
